GALAPAGOS
Galapagos NV develops medicines for oncology and immunology, primarily in the US and Europe. Their pipeline includes GLPG3667, GLPG5101, GLPG5201, and GLPG5301, all CAR-T product candidates. These products are in various stages of Phase 1/2 trials for different types of cancer. The company has collaboration agreements with Gilead Sciences and AbbVie.
Overview
Strengths
- Current Price to Earnings Ratio (4.84) is lower than the sector mean (91.15).
- Price to book ratio (0.48) is lower than the sector mean (24.44).
- EV/EBITDA (2.44) is lower than the sector mean (85.60).
- EV/EBIT (4.86) is lower than the sector mean.
- Strong EBITDA Margin of 54.36%.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
Key Financial Data